Pharmagen, Inc.
Pharmagen, Inc.
Your view on PHRX
Overview
What the company does, where it operates, and who runs it.
About Pharmagen, Inc.
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Mackie A. Barch
- Headquarters
- 9337 Fraser Avenue, Silver Spring, MD, US
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Mackie A. Barch
- Headquarters
- 9337 Fraser Avenue, Silver Spring, MD, US
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals.
It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes.
The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin.
In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs.
The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Pharmagen, Inc., and the rating behind it. PHRX last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Pharmagen, Inc.. Starting points for Pharmagen, Inc.: EPS -$0.02, beta 0.28 — an Medical - Distribution name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Pharmagen, Inc.. Pharmagen, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Pharmagen, Inc.. Trailing twelve-month EPS for Pharmagen, Inc. stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Pharmagen, Inc.. Pharmagen, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Pharmagen, Inc. valued side by side against its closest peers. Pharmagen, Inc. is measured against Medical - Distribution peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Pharmagen, Inc., and how their positions are changing. At a $5,171 market value, institutional positions materially move Pharmagen, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Pharmagen, Inc. executives and directors. Shares of Pharmagen, Inc. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Pharmagen, Inc.. Pharmagen, Inc. is a $5,171 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Pharmagen, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Pharmagen, Inc.. Coverage tracks Pharmagen, Inc. within Medical - Distribution (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.